Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D.

We love to hear from our listeners. Send us a message. In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies.  Subscribe to the podcast! Apple  |  Spotify |  YouTube Visit my website: Cell & Gene Connect with me on LinkedIn